MEDICLIN
Market Cap
€191.0m
Last Updated
2021/01/21 19:16 UTC
Data Sources
Company Financials +
Executive Summary
MEDICLIN Aktiengesellschaft operates hospitals in Germany. More Details
Rewards
Risk Analysis
Snowflake Analysis
Fair value with moderate growth potential.
Share Price & News
How has MEDICLIN's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MED is less volatile than 75% of German stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: MED's weekly volatility (3%) has been stable over the past year.
Market Performance
7 Day Return
-3.5%
MED
-0.9%
DE Healthcare
0.4%
DE Market
1 Year Return
-25.4%
MED
-11.0%
DE Healthcare
4.9%
DE Market
Return vs Industry: MED underperformed the German Healthcare industry which returned -11% over the past year.
Return vs Market: MED underperformed the German Market which returned 3.6% over the past year.
Shareholder returns
| MED | Industry | Market | |
|---|---|---|---|
| 7 Day | -3.5% | -0.9% | 0.4% |
| 30 Day | 3.2% | 1.4% | 4.8% |
| 90 Day | -0.5% | 5.0% | 12.2% |
| 1 Year | -25.4%-25.4% | -9.2%-11.0% | 8.2%4.9% |
| 3 Year | -34.2%-35.3% | -30.3%-33.7% | 6.5%-2.8% |
| 5 Year | -9.2%-10.8% | -21.0%-26.1% | 45.0%24.7% |
Long-Term Price Volatility Vs. Market
How volatile is MEDICLIN's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall St
MEDICLIN's (ETR:MED) Stock Price Has Reduced 44% In The Past Three Years2 months ago | Simply Wall St
Health Check: How Prudently Does MEDICLIN (ETR:MED) Use Debt?5 months ago | Simply Wall St
What To Know Before Buying MEDICLIN Aktiengesellschaft (ETR:MED) For Its DividendValuation
Is MEDICLIN undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: MED (€3.88) is trading below our estimate of fair value (€103.36)
Significantly Below Fair Value: MED is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: MED is unprofitable, so we can't compare its PE Ratio to the DE Healthcare industry average.
PE vs Market: MED is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MED's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MED is good value based on its PB Ratio (1x) compared to the DE Healthcare industry average (1.4x).
Next Steps
Future Growth
How is MEDICLIN forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
104.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MED is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.07%).
Earnings vs Market: MED is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: MED's is expected to become profitable in the next 3 years.
Revenue vs Market: MED's revenue (4.9% per year) is forecast to grow slower than the German market (6% per year).
High Growth Revenue: MED's revenue (4.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MED's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has MEDICLIN performed over the past 5 years?
-38.3%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MED is currently unprofitable.
Growing Profit Margin: MED is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MED is unprofitable, and losses have increased over the past 5 years at a rate of 38.3% per year.
Accelerating Growth: Unable to compare MED's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MED is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (5.4%).
Return on Equity
High ROE: MED has a negative Return on Equity (-0.29%), as it is currently unprofitable.
Next Steps
Financial Health
How is MEDICLIN's financial position?
Financial Position Analysis
Short Term Liabilities: MED's short term assets (€213.1M) exceed its short term liabilities (€186.3M).
Long Term Liabilities: MED's short term assets (€213.1M) do not cover its long term liabilities (€542.3M).
Debt to Equity History and Analysis
Debt Level: MED's debt to equity ratio (53.9%) is considered high.
Reducing Debt: MED's debt to equity ratio has increased from 28.9% to 53.9% over the past 5 years.
Debt Coverage: MED's debt is well covered by operating cash flow (112.9%).
Interest Coverage: Insufficient data to determine if MED's interest payments on its debt are well covered by EBIT.
Balance Sheet
Next Steps
Dividend
What is MEDICLIN current dividend yield, its reliability and sustainability?
1.29%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: MED's dividend (1.29%) is higher than the bottom 25% of dividend payers in the German market (0.97%).
High Dividend: MED's dividend (1.29%) is low compared to the top 25% of dividend payers in the German market (3.5%).
Stability and Growth of Payments
Stable Dividend: MED's dividend payments have been volatile in the past 10 years.
Growing Dividend: MED's dividend payments have not increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: MED is paying a dividend but the company is unprofitable.
Future Payout to Shareholders
Future Dividend Coverage: MED's dividends in 3 years are forecast to be well covered by earnings (16.6% payout ratio).
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.0yrs
Average management tenure
CEO
Volker Hippler (50 yo)
4.75yrs
Tenure
Mr. Volker Hippler has been Chairman of Management Board at MEDICLIN Aktiengesellschaft since April 1, 2016 and has been its CEO since April 2016. Mr. Hippler worked in a consulting company focussing on he...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of Management Board & CEO | 4.75yrs | no data | no data | |
| CFO & Member of the Management Board | 2.33yrs | no data | no data | |
| Head of Group Accounting | no data | no data | no data | |
| Head of Internal Audit | 1yr | no data | no data | |
| Head of Law | 1yr | no data | no data | |
| Head of Corporate Communications & Press Spokeswoman | 1yr | no data | no data | |
| Head of Purchasing & Medical Technology | 1yr | no data | no data | |
| Head of Payroll & Application Management | 1yr | no data | no data | |
| Head of Finance & Accounting | 1yr | no data | no data | |
| Head of Group Controlling | 1yr | no data | no data | |
| Head of Taxes | 1yr | no data | no data |
1.0yrs
Average Tenure
Experienced Management: MED's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Member of Advisory Board | no data | no data | no data | |
| Deputy Chairman of Supervisory Board | 18.67yrs | no data | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Supervisory Board | 6.25yrs | €10.75k | no data | |
| Member of the Supervisory Board | 15.67yrs | €14.25k | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Employee Representative Member of Supervisory Board | 8.33yrs | €12.26k | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Employee Representative Member of Supervisory Board | 8.33yrs | €12.00k | no data | |
| Employee Representative Member of Supervisory Board | 6.42yrs | €12.74k | no data | |
| Chairman of the Supervisory Board | 1.17yrs | no data | no data |
8.3yrs
Average Tenure
Experienced Board: MED's board of directors are considered experienced (8.3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
MEDICLIN Aktiengesellschaft's company bio, employee growth, exchange listings and data sources
Key Information
- Name: MEDICLIN Aktiengesellschaft
- Ticker: MED
- Exchange: XTRA
- Founded: NaN
- Industry: Health Care Facilities
- Sector: Healthcare
- Market Cap: €190.950m
- Shares outstanding: 47.50m
- Website: https://www.mediclin.de
Number of Employees
Location
- MEDICLIN Aktiengesellschaft
- Okenstrasse 27
- Offenburg
- Baden-Württemberg
- 77652
- Germany
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| MED | DB (Deutsche Boerse AG) | Yes | Bearer Shares | DE | EUR | Dec 2000 |
| MED | XTRA (XETRA Trading Platform) | Yes | Bearer Shares | DE | EUR | Dec 2000 |
| 0NDG | LSE (London Stock Exchange) | Yes | Bearer Shares | GB | EUR | Dec 2000 |
Biography
MEDICLIN Aktiengesellschaft operates hospitals in Germany. It operates through Post-Acute, Acute, and Other Activities segments. The company offers medical services focusing on cardiology, cardiac surgery,...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/21 19:16 |
| End of Day Share Price | 2021/01/21 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.